Top Tech Companies (1,916)
Don't see your company?
Create a company profile
Tioga Pharmaceuticals develops therapies for the treatment of gastrointestinal diseases.
At Promega Corporation, creativity and connection drive discovery and innovation. We celebrate scientific discovery and the creative application of science to solve problems. Interactions with our customers, partners and vendors are central to everything we do, and we value those relationships. We seek out and build connections across the globe and in our local communities because creative problem solving requires a network of diverse ideas and viewpoints.
At Sony Biotechnology, our flow cytometry and imaging products reflect our full commitment to produce and support high quality, innovative products to support advanced biomedical research. Founded in 1995, we are based in San Jose, California with affiliate offices in Japan, China and Europe. Innovation Research and Development as well as engineering teams are based in Japan. Their innovative approaches and technical know-how is incorporated into our product platforms has been recognized in patents as well as numerous technology and design awards. For example, to improve stability, our systems allow direct monitoring of particle flow status using technology originally developed for the Blu-ray disk that delivers error free performance while operating at very high speed. In conventional flow cytometers, this accuracy largely depends on skillful operators. To deliver very low noise electronics, our systems incorporate technologies that have brought pure, true sound to music. This Sony know-how reduces signal noise from the electric circuit currents to achieve very low noise electronics so that rogue signal noise does not get in the way of delivering accurate results to scientists. Importantly, our innovations also come from looking beyond the conventional made possible by constant sensing and deep study of advanced technologies for superior solutions to customer challenges. Our use of microfluidics and spectral analysis are two examples of this innovative approach to product design and development.
NovaSys is a contracted healthcare provider.
NEOGEN Corporation develops and markets products dedicated to food and animal safety. The company’s Food Safety Division markets dehydrated culture media and diagnostic test kits to detect foodborne bacteria, natural toxins, genetic modifications, food allergens, drug residues, plant diseases and sanitation concerns. NEOGEN’s Animal Safety Division markets a complete line of diagnostics, veterinary instruments, veterinary pharmaceuticals, nutritional supplements, disinfectants and rodenticides.
United BioChannels specializes in developing and implementing marketing & sales strategies for life science companies.
Kiyatec is disrupting cancer care by accurately predicting patient–specific response and non–response before treatment begins. We utilize the patient’s own living tumor cells to create functional 3D models to test a battery of cancer therapies in our CLIA-certified and research laboratories. Our goal is to enable physicians to isolate only the effective treatments for their patients as quickly as possible - making true personalized medicine a reality. Our approach has been validated through engagements with leading cancer hospitals, multiple top 10 pharmaceutical companies and the NCI. We are conducting robust clinical trials to fully demonstrate the power of our approach and earn widespread adoption for a broad portfolio of products predicting response to today’s and tomorrow’s therapies. www.kiyatec.com
ChemDiv offers flexible business models that helps you to manage development risk.
NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research. The company's technology enables a wide variety of basic research and translational medicine applications. NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection. In 2019, the company launched the GeoMx™ Digital Spatial Profiler enabling highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections.
Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. For more information, visit www.deciphera.com
Ardelyx is a publicly traded biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs. Ardelyx's first approved product, IBSRELA® (tenapanor) is available in the United States. Ardelyx is developing XPHOZAH® (tenapanor), a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, which has completed three successful Phase 3 trials. Ardelyx has a Phase 2 potassium secretagogue program, RDX013, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease and an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in their respective territories.
Dignify Therapeutics is a drug development company focused on delivering novel drug therapies for bladder and bowel disorders in spinal.
Biotechnology startup developing automated species identification technologies for AgTech, BioTech, and Environmental monitoring sectors.
Aristea Therapeutics is a developer of novel therapies created for autoimmune diseases.
For people who believe eating healthier should be effortless and tasty, The Not Company is a Foodtech, that reinvents animal-based foods using only plants. Unlike traditional food businesses, our company uses technology to recreate the same products we love to eat in a natural, sustainable and affordable way, keeping it functional, easy to use and mouthwateringly delicious.
Collaborative XR Software Platform for Molecular Design. Next step in computational/medicinal chemistry, structural biology, and beyond.
We are a pioneering healthcare company that aims to transform health through the power of genomics. The company was formed in 2014 by four world-leading statistical and human geneticists at the University of Oxford, including Professor Sir Peter Donnelly and Professor Gil McVean. We use large-scale genetic information to realise preventative medicine and improve drug discovery. We're a world-leader in genomic prevention: a paradigm-changing approach to sustainable healthcare which for the first time allows reliable, personalized estimates of risk for all the common diseases and cancers, well ahead of disease manifestation, allowing accurate and early interventions and tailored screening. Our proprietary algorithms and databases offer something no competitor can: the ability to accurately link minute variation across the entire genome to changes in thousands of biological measurements and disease outcomes, to generate population-level insights for healthcare systems, individual-level insights for clinicians about the risk of common diseases, and new understanding of disease processes. In August 2018, we announced a multi-year collaboration with Vertex to use human genetics and data science to advance discovery of precision medicines. We also has several pilot programmes in development within UK and US healthcare systems. Our team is a multi-disciplinary group focused on finding powerful and creative solutions for bringing subject-leading science to as wide an audience as possible, and, in doing so, offer the chance of transforming lives around the world. The workforce is highly qualified and consists of over 90 people, including genomic scientists, computational biologists, statisticians, software engineers, product developers, data scientists and commercial strategists. We are headquartered in Oxford, with offices in Cambridge (UK) and Boston (US).
AgonOx is a cure for many types of cancer will be found through harnessing the power of the immune system
Encoded Therapeutics is creating one-time, disease-modifying gene therapies for pediatric central nervous system (CNS) disorders with its cell-selective targeting and regulation platform. The Encoded approach offers potentially unprecedented gene specificity and cell selectivity to unlock novel opportunities by targeting a range of disease mechanisms. Encoded’s technology is compatible with any delivery system to control where and when therapeutic transgenes are expressed, thereby shaping the functionality of target cells and holding broader therapeutic potential beyond CNS disorders. For more information, please visit www.encoded.com, and follow us on LinkedIn, Twitter @EncodedTx and YouTube. Social media guidelines: https://encoded.com/social-media-community-guidelines/
argenx is a global immunology company committed to improving the lives of people living with severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx is translating immunology breakthroughs into a world-class portfolio of novel antibody-based medicines.
